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NEUROSURGERY

he authors1 have used a large, granular
database to examine opioid use before and
after successful spinal cord stimulation
(SCS) belonging to the period 2010 to 2015,
before there was wide recognition of the opioid
epidemic.2 On average, patients who underwent
SCS were able to significantly reduce opioid use
1 yr after implant. However, patients with longterm, higher preoperative opioid use and a higher
body mass index were less likely to have reduced
opioid use.
As with any analysis that includes private
insurers, people who lose their insurance over
the time period examined are not included,
potentially leading to bias, since patients who
did not do well might be more likely to lose
their insurance over the year after surgery. Since
this potentially represented 26% of the patient
population (Figure 11 ), this bias should not be
underestimated. In addition, patients who had
their systems explanted within a year (5%) were
excluded, so these data cannot be used to counsel
patients who are considering SCS, since it was
not an intent-to-treat analysis.
In addition, the authors assume that similar
patients who do not undergo SCS placement
would have no reduction in their opioid use
without SCS. This might not be the case.
This was the initial assumption for Kemler and
colleagues’ paper on SCS for complex regional
pain syndrome (CRPS), resulting in a publication in The New England Journal of Medicine.3
However, the long-term results showed no
difference between the control and the stimulation groups.4 The natural history of CRPS
with aggressive physical therapy was better than
anyone had thought. The opioid reduction seen
in this paper could also be a result of patients
moving from pain management by their primary
care providers to more expert pain practitioners

T

who perform SCS and would be expected to be
more focused on opioid reduction.
I disagree with the authors that they could
not obtain a matched cohort in this database
as a comparison due to the lack of granularity
of the data. While it would have limitations,
patients with similar demographics, diagnostic
codes, opioid-use patterns, and comorbidities
could be a useful comparison group.
The authors are to be congratulated for this
important early step in showing the possibility of
SCS in reducing opioid use, especially if implemented before patients progress to higher dosing.
However, there is more work to be done to prove
causality.
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